Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 14:2020:7136802.
doi: 10.1155/2020/7136802. eCollection 2020.

Percutaneous Atrial Septal Defect Closure Using the Occlutech Figulla Device in Adults: More than 800 Patient-Years of Follow-Up

R J R Snijder  1 , L E Renes  2 , D Bosshardt  1 , M J Suttorp  1 , J M Ten Berg  1 , M C Post  1
Affiliations

Percutaneous Atrial Septal Defect Closure Using the Occlutech Figulla Device in Adults: More than 800 Patient-Years of Follow-Up

R J R Snijder et al. J Interv Cardiol. .

Abstract

Purpose: The Occlutech Figulla occluder has been proven safe and effective at midterm follow-up after percutaneous atrial septal defect (ASD) closure. We describe the safety and efficacy at long-term follow-up in adults.

Methods: All consecutive adult patients that underwent ASD closure between 2008 and 2015 were included. All complications were registered. Residual left-to-right shunt (LRS) was diagnosed using color-Doppler transthoracic echocardiography (TTE). Right-to-left shunting was diagnosed using contrast TTE. Successful closure was defined as no LRS at follow-up.

Results: In total, 166 patients (mean age 56.7 ± 16.1 years; 62% female) underwent percutaneous ASD closure using the Occlutech Flex I (70%) or Flex II (30%) device (diameter 24 mm; range 10-40 mm) under general anaesthesia and transoesophageal echocardiographic guidance. Long-term follow-up data were available for 144 patients (87%) with a mean follow-up of 5.9 ± 2.6 years, a total of 814 patient-years. During hospitalization, device embolization occurred in three patients (1.8%) with successful extraction in all. During the long-term follow-up, 15 patients (9.8%) suffered new-onset atrial fibrillation and stroke occurred in 2.1%. There was no residual LRS at 12-month follow-up. No device embolization occurred during the long-term follow-up.

Conclusion: Percutaneous ASD closure using the Occlutech device appears to be safe at long-term follow-up with a high successful closure rate at one year.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

References

    1. Snijder R. J., Suttorp M. J., Ten Berg J. M., Post M. C. Percutaneous closure of secundum type atrial septal defects: more than 5-year follow-up. World Journal of Cardiology. 2015;7(3):150–156. doi: 10.4330/wjc.v7.i3.150. - DOI - PMC - PubMed
    1. Pac A., Polat T. B., Cetin I., Oflaz M. B., Balli S. Figulla ASD Occluder versus amplatzer septal occluder: a comparative study on validation of a novel device for percutaneous closure of atrial septal defects. Journal of Interventional Cardiology. 2009;22(6):489–495. doi: 10.1111/j.1540-8183.2009.00497.x. - DOI - PubMed
    1. Godart F., Houeijeh A., Recher M., et al. Transcatheter closure of atrial septal defect with the figulla ASD occluder: a comparative study with the amplatzer septal occluder. Archives of Cardiovascular Diseases. 2015;108(1):57–63. doi: 10.1016/j.acvd.2014.09.005. - DOI - PubMed
    1. Roymanee S., Promphan W., Tonklang N., Wongwaitaweewong K. Comparison of the Occlutech figulla septal occluder and amplatzer septal occluder for atrial septal defect device closure. Pediatric Cardiology. 2015;36(5):935–941. doi: 10.1007/s00246-015-1103-y. - DOI - PubMed
    1. Aytemir K., Oto A., Ozkutlu S., et al. Transcatheter interatrial septal defect closure in a large cohort: midterm follow-up results. Congenital Heart Disease. 2013;8:418–427. - PubMed

MeSH terms